• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IQVIA Institute Analyzes Unprecedented Speed of COVID-19 Vaccine Trials

IQVIA Institute Analyzes Unprecedented Speed of COVID-19 Vaccine Trials

May 2, 2022

The IQVIA Institute for Health Data Science has come out with a new report that looks back at the historic timelines achieved by the COVID-19 vaccine trials, outlining lessons learned from the unprecedented research effort that have application now and in future research.

The report highlights a major factor in the acceleration of COVID-19 vaccine development speeds: the reduction of “white space” by the near-immediate initiation of phase 2 and 3 trials after phase 1 starts, as well as submitting for Emergency Use Authorization the moment enough safety and efficacy data had been gathered. This was additionally supported by high responsiveness on the part of sites, sponsors, vendors and regulatory agencies, the report notes.

The IQVIA Institute attributes about half of this reduction of white space to vaccine acceleration; rapid trial timelines, reached through “shifts in operational actions, organizational alignment and delivery-model drivers,” accounted for the other half. Supporting this point, the institute cited an analysis of the acceleration of phase 2 and 3 trials across a set of COVID-19 trials that found an average time saving of 26 months.

“The COVID-19 vaccine development experience and analysis surfaced a range of behavioral, organizational and operational changes that are expected to have relevancy in accelerating ongoing value delivery from the industry pipeline,” the report concludes. “While many of these changes were precipitated by unique environmental enablers, many are repeatable outside of the context of the pandemic.”

Access the report here: https://bit.ly/3EUtOY0.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing